The discovery of constitutive activity of the BRAF-MEK-ERK signalling pathway in melanomagenesis emphasizes the importance of these signalling pathway intermediates as potential therapeutic targets in treating melanoma especially those that have become resistant to BRAFV600E inhibitors. This evidence concerns the gene BRAF and melanoma.